PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a leader in precision oncology, announced that David H. Mack, Ph.D., will participate in a "Fireside Chat" at the Evercore ISI 4th Annual HealthCONx Conference from November 30 to December 2, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a leader in precision oncology, announced that David H. Mack, Ph.D., will participate in a "Fireside Chat" at the Evercore ISI 4th Annual HealthCONx Conference from November 30 to December 2, 2021. The chat is scheduled for December 2, 2021, at 11:20 am ET. PMV Pharma specializes in developing small molecule therapies targeting p53 mutations, which are prevalent in about half of all cancers. This event will also include one-on-one investor meetings.
Details
News Market Reaction – PMVP
The recorded move for PMVP in the trading session of this news was -2.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CRANBURY, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will represent PMV Pharma in a “Fireside Chat” at the Evercore ISI 4th Annual HealthCONx Conference taking place November 30 – December 2, 2021. The company will also participate in one-on-one investor meetings at the conference.
Details on the presentation can be found below.
| Evercore ISI 4th Annual HealthCONx Conference | |
| Date: | Thursday, December 2, 2021 |
| Time: | 11:20 am ET |
| Format: | Fireside Chat |
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Contact
For Investors:
Winston Kung
Chief Financial Officer
investors@pmvpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.